FIELD NOTE
Medicare's lab pay reset finally lands, and molecular diagnostics absorb the deepest cuts.
CMS posted preliminary Clinical Laboratory Fee Schedule rates for 2027 on Monday. Of roughly 1,500 codes with usable private-payer data, 1,171 came back with a weighted median below what Medicare pays today. Another 186 went up, 169 held flat, and 419 returned no usable data at all — those go to an expert panel CMS convened on September 15 and 16. The agency’s own summary puts the average potential change at about 16 percent below current rates.
CMS framed it as a correction rather than a cut. Administrator Mehmet Oz said Medicare has been paying roughly 16 percent more than commercial insurers for identical tests, and the agency estimated the adjustment saves taxpayers about $1 billion a year. Statute caps any single test at a 15 percent reduction per year, so the full repricing phases across 2027, 2028 and 2029. The American Clinical Laboratory Association counts 775 tests that hit that ceiling in year one. Quest Diagnostics closed down nearly 5 percent on the news; Labcorp fell more than 3 percent.
The damage is not evenly distributed, and that is the part device leaders should read closely. Routine chemistry lands near the 16 percent average. Molecular pathology and genomic sequencing panels face steeper reductions. Proprietary laboratory analyses — the PLA codes a company obtains for a single branded assay — move barely 2 percent. The spread rewards exactly what it looks like it rewards: a test with its own code, its own evidence file and no direct comparator holds its price. A test that sits in a crowded code with a dozen competitors reporting rates does not.
What makes this cycle different is that it is happening at all. PAMA passed in 2014 and produced three years of cuts up to 10 percent, then six years of freezes as Congress delayed the mechanism almost annually. The most recent delay rode in on the bill that ended the government shutdown, signed February 3, 2026, which blocked the 2026 cuts and pushed the data reporting window to May 1. Labs reported through the end of July; 6,411 NPIs submitted, 6,304 survived quality screening. The bipartisan RESULTS Act would cap annual reductions at 5 percent, exclude Medicaid managed care rates from the reporting pool, and move rate-setting to a four-year cycle. It carries 121 House cosponsors and has not moved out of committee.
So the industry’s argument now has to be made against the data rather than against the schedule, and the industry does not like the data. ACLA calls the sample “a distorted and incomplete picture of the market,” noting the rates rest on reporting from roughly 2 percent of labs Medicare Part B paid in 2024.
There is a wrinkle in that complaint worth flagging, because it cuts the other way. Hospital outreach labs, which commercial plans reimburse at multiples of independent lab rates, made up 13.6 percent of the reporting pool this cycle — 875 of 6,411 labs — against 1.1 percent in 2017. Their participation pulled the weighted medians up. The cuts landing in November are already the moderated version. Had the reporting pool looked like it did in the first cycle, the numbers would be worse.
For anyone whose commercial model runs through a CLFS code, the practical read is narrow and immediate. The comment window is 30 days from September 21. CMS finalizes in November. Rates take effect January 1. That is not enough time to change the arithmetic, and comment letters have not historically moved preliminary CLFS rates much. What it is enough time for is to find out which of your codes are in the 775, model the three-year glide rather than the first-year hit, and decide whether the assay you are building a business around survives the rate it will be paid in 2029.
The larger signal is about where diagnostics value gets defended. Reimbursement built on a market-rate benchmark punishes commodity positioning by design, and the benchmark is now running on schedule after nine years of not running. Differentiation that exists only in a sales deck will price like a commodity, because the code it bills under is a commodity. Differentiation that exists in a distinct code, backed by evidence a payer can read, is the only thing in this rate file that held its value.
SPONSORED BY RŌG HEALTH
Most device companies don’t fail on technology. They fail on sequencing.
The gaps that stall a raise or a hospital deal are usually visible months earlier: an unclear buyer, thin evidence, economics nobody has pressure-tested. They're cheap to fix early and expensive to fix mid-deal.
RŌG Health rebuilt its free Commercial Readiness Check to find them. Seven questions, about two minutes. You get a score out of 15, a profile across five commercial areas showing where you're most exposed, and a read on what to settle first given your next milestone and how soon it is. No pitch at the end. If you want to talk through your answers, you can book a 20-minute call from the results page.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.